Clinical TrialParallelKetamineKetaminePlaceboCompleted
CAP-Ketamine for Antidepressant Resistant PTSD
The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an active duty military and Veteran population.
Target Enrollment
Not specified
Study Type
Phase II interventional
Design
Randomized
Registry
Study Arms & Interventions
Standard Dose
experimentalKetamine 0.5 mg/kg administered via 8 intravenous infusions, twice weekly.
Interventions
- Ketamine0.5 mg/kgvia IV• twice weekly• 8 doses total
8 infusions total
Low Dose
experimentalKetamine 0.2 mg/kg administered via 8 intravenous infusions, twice weekly.
Interventions
- Ketamine0.2 mg/kgvia IV• twice weekly• 8 doses total
8 infusions total
Placebo
placeboIntravenous placebo (normal saline) administered twice weekly.
Interventions
- Placebovia IV• twice weekly• 8 doses total
normal saline
Study Details
- StatusCompleted
- PhasePhase II
- Typeinterventional
- DesignRandomized
- TimelineStart: 2016-04-18End: 2020-07-01
- Compounds
Study Team
Sponsors & Collaborators
- VA Office of Research and DevelopmentPrimary Sponsor